Destiny Pharma Floats on UK AIM And Completes China Deal

 
• By John Davis

An agreement covering the development and commercialization of its products in China underlines the potential of now-publicly listed Destiny Pharma’s investigational antibacterial to evade the emergence of resistance.

Index
• Source: Shutterstock

More from Deals

More from Business